@article{74d2ac63d25245b2a13f5df663b25c8f,
title = "The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer",
author = "Ahn, {Daniel H.} and Tanios Bekaii-Saab",
note = "Funding Information: personal fees from Exelixis, Eisai, Daiichi Sankyo, Genentech, Advanced Accelerator Applications, Novartis, Imuneering, and Ipsen as well as research funding from AstraZeneca and Bayer outside the submitted work. Dr Bekaii-Saab reported research funding from Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, and BMS; consulting fees from Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, Merck, Stemline, AbbVie, Boehringer Ingelheim, Janssen, Daichii Sankyo, Natera, TreosBio, Celularity, Exact Science, Sobi, Beigene, Kanaph, AstraZeneca, Deciphera, MJH Life Sciences, Aptitude Health, Illumina and Foundation Medicine; committee and board service for Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Merck/Eisai, PanCan, 1Globe, Imugene, Immuneering, Xilis, Replimune Artiva, and Sun Biopharma; royalties from UpToDate; and patents with Imugene and Recursion.",
year = "2022",
month = sep,
doi = "10.1001/jamaoncol.2022.2309",
language = "English (US)",
volume = "8",
pages = "1257--1259",
journal = "JAMA Oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "9",
}